Research advances in application of mesenchymal stem cells for aging related diseases

doi:10.16352/j.issn.1001-6325.2023.01.0038

Abstract

Abstract: Aging related diseases seriously affect the health of the elderly. Studies on the roles and mechanisms of mesenchymal stem cells (MSCs) in aging related diseases have attracted more and more attention. Besides, a number of relative clinical trials have been carried out in the domestic and overseas. This review summarizes the roles, molecular mechanisms, clinical trials of MSCs and MSCs-derived exosomes in several typical age-related diseases such as osteoporosis, Alzheimer's disease, Parkinson's disease, type 2 diabetes, atherosclerosis, chronic obstruc-tive pulmonary disease and tumor. This review may provide some theoretical reference and advices for future studies of MSCs in aging related diseases.

Key words: mesenchymal stem cells(MSCs), aging related diseases, exosome

CLC Number:

R329.28

SHANG Lipeng, LIU Guoxiang, DING Xiaoyan, LI Bing, ZHAO Chunhua, LI Xiaoxia. Research advances in application of mesenchymal stem cells for aging related diseases[J]. Basic & Clinical Medicine, 2023, 43(1): 38-45.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.01.0038

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I1/38

References

[1] Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation[J]. Nature, 2016, 539:180-186.
[2] Lopez-Otin C, Blasco MA, Partridge L, et al. The hallmarks of aging[J]. Cell, 2013, 153:1194-1217.
[3] Krampera M, Le Blanc K. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy[J]. Cell Stem Cell, 2021, 28:1708-1725.
[4] Han Y, Yang J, Fang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases[J]. Signal Transduct Target Ther, 2022, 7:92-110.
[5] Piffoux M, Volatron J, Cherukula K,et al. Engineering and loading therapeutic extracellular vesicles for clinical translation: A data reporting frame for comparability[J]. Adv Drug Deliv Rev, 2021, 178:113972-113980.
[6] Staff NP, Jones DT, Singer W. Mesenchymal stromal cell therapies for neurodegenerative diseases[J]. Mayo Clin Proc, 2019, 94:892-905.
[7] Malekpour K, Hazrati A, Zahar M, et al. The potential use of mesenchymal stem cells and their derived exosomes for orthopedic diseases treatment[J]. Stem Cell Rev Rep, 2022, 18:933-951.
[8] Sun Y, Shi H, Yin S, et al. Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving beta-cell destruction[J]. ACS Nano, 2018, 12:7613-7628.
[9] Arthur A, Gronthos S. Clinical application of bone marrow mesenchymal stem/stromal cells to repair skeletal tissue[J]. Int J of Mol Sci, 2020, 21:9759-9786.
[10] Jiang Y, Zhang P, Zhang X, et al. Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis[J]. Cell Prolif, 2021, 54:12956-12975.
[11] Li H, Fan J, Fan L, et al. MiRNA-10b reciprocally stimulates osteogenesis and inhibits adipogenesis partly through the TGF-beta/SMAD2 signaling pathway[J]. Aging Dis, 2018, 9:1058-1073.
[12] Fricova D, Korchak JA, Zubair AC. Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease[J]. NPJ Regen Med, 2020, 5:20-29.
[13] Chen HX, Liang FC, Gu P, et al. Exosomes derived from mesenchymal stem cells repair a Parkinson's disease model by inducing autophagy[J]. Cell Death Dis, 2020, 11:288-304.
[14] Xue C, Li X, Ba L et al. MSCs-derived exosomes can enhance the angiogenesis of human brain MECs and show therapeutic potential in a mouse model of parkinson's disease[J]. Aging Dis, 2021, 12:1211-1222.
[15] Park KS, Bandeira E, Shelke GV, et al. Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles[J]. Stem Cell Res Ther, 2019, 10:288-302.
[16] Si Y, Zhao Y, Hao H, et al. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity[J]. Diabetes, 2012, 61:1616-1625.
[17] Li H, Zhu H, Ge T, et al. Mesenchymal stem cell-based therapy for diabetes mellitus: enhancement strategies and future perspectives[J]. Stem Cell Rev Reports, 2021, 17:1552-1569.
[18] Zhang Y, Chen W, Feng B, et al. The clinical efficacy and safety of stem cell therapy for diabetes mellitus: a systematic review and meta-analysis[J]. Aging Dis, 2020, 11:141-153.
[19] Lin Y, Zhu W, Chen X. The involving progress of MSCs based therapy in atherosclerosis[J]. Stem Cell Res Ther, 2020, 11:216-228.
[20] 林颖, 胡豪畅, 成绩, 等. 间充质干细胞治疗动脉粥样硬化的研究进展[J]. 中华心血管病杂志, 2021, 49:288-292.doi: 10.3760/cma.j.cn112148-20210129-00106.
[21] Rahmani A, Saleki K, Javanmehr N, et al. Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous and vascular systems in stroke[J]. Ageing Res Rev, 2020, 62:101106-101126.
[22] Takafuji Y, Hori M, Mizuno T, et al. Humoral factors secreted from adipose tissue-derived mesenchymal stem cells ameliorate atherosclerosis in Ldlr^-/- mice[J]. Cardiovasc Res, 2019, 115:1041-1051.
[23] Xiao X, Xu M, Yu H, et al. Mesenchymal stem cell-derived small extracellular vesicles mitigate oxidative stress-induced senescence in endothelial cells via regulation of miR-146a/Src[J]. Signal Transduct Target Ther, 2021, 6:354-368.
[24] Ma J, Chen L, Zhu X, et al. Mesenchymal stem cell-derived exosomal miR-21a-5p promotes M2 macrophage polarization and reduces macrophage infiltration to attenuate atherosclerosis[J]. Acta Biochim Biophys Sin(Shanghai), 2021, 53:1227-1236.
[25] Li J, Xue H, Li T, et al. Exosomes derived from mesenchymal stem cells attenuate the progression of atherosclerosis in ApoE(-/-) mice via miR-let7 mediated infiltration and polarization of M2 macrophage[J]. Biochem Biophys Res Commun, 2019, 510:565-572.
[26] Chen YT, Miao K, Zhou L, et al. Stem cell therapy for chronic obstructive pulmonary disease[J]. Chin Med J (Engl), 2021, 134:1535-1545.
[27] Abbaszadeh H, Ghorbani F, Abbaspour-Aghdam S, et al. Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools[J]. Stem Cell Res Ther, 2022, 13:262-276.
[28] Harrell CR, Miloradovic D, Sadikot R, et al. Molecular and cellular mechanisms responsible for beneficial effects of mesenchymal stem cell-derived product “Exo-d-MAPPS” in attenuation of chronic airway inflammation[J]. Anal Cell Pathol (Amst), 2020, 2020:3153891-3153905.
[29] Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease[J]. Expert Rev Respir Med, 2020, 14:31-39.
[30] Squassoni SD, Sekiya EJ, Fiss E,et al. Autologous infusion of bone marrow and mesenchymal stromal cells in patients with chronic obstructive pulmonary disease: phase i randomized clinical trial[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16:3561-3574.
[31] Yin W, Wang J, Jiang L, et al. Cancer and stem cells[J]. Exp Biol Med (Maywood), 2021, 246:1791-1801.
[32] Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12:31-46.
[33] Shi Y, Du L, Lin L, et al. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets[J]. Nat Rev Drug Discov, 2017, 16:35-52.
[34] Timaner M, Tsai KK, Shaked Y. The multifaceted role of mesenchymal stem cells in cancer[J]. Semin Cancer Biol, 2020, 60:225-237.
[35] Lu L, Chen G, Yang J, et al. Bone marrow mesenchymal stem cells suppress growth and promote the apoptosis of glioma U251 cells through downregulation of the PI3K/AKT signaling pathway[J]. Biomed Pharmacother, 2019, 112-108625-108638.
[36] Hughes RM, Simons BW, Khan H,et al. Asporin restricts mesenchymal stromal cell differentiation, alters the tumor microenvironment, and drives metastatic progression[J]. Cancer Res, 2019, 79:3636-3650.
[37] Lan T, Luo M, Wei X. Mesenchymal stem/stromal cells in cancer therapy[J]. J Hematol Oncol, 2021, 14:195-210.
[38] Li X, Sun Z, Peng G,et al. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast sub-group associated with poor clinical outcomes in patients with gastric cancer[J]. Theranostics, 2022, 12:620-638.
[39] Takayama Y, Kusamori K, Nishikawa M. Mesenchymal stem/stromal cells as next-generation drug delivery vehicles for cancer therapeutics[J]. Expert Opin Drug Deliv, 2021, 18:1627-1642.
[40] Whiteside TL. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment[J]. Semin Immunol, 2018, 35:69-79.
[41] Madl CM, Heilshorn SC, Blau HM. Bioengineering strategies to accelerate stem cell therapeutics[J]. Nature, 2018, 557:335-342.
[42] Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases[J]. Nat Rev Nephrol, 2018, 14:493-507.